Indian Medical Testing Company Neuberg Diagnostics Eyes Public Stock Offering

Chennai-based medical diagnostics firm Neuberg Diagnostics announced plans to launch an initial public offering within the next six months. The company aims to capitalize on India's rapidly expanding healthcare market, driven by an aging population and rising chronic disease rates.

A major Indian medical testing company is preparing to enter the stock market, with executives announcing their intention to launch a public offering by late 2025 or early 2027 at the latest.

Neuberg Diagnostics, headquartered in Chennai, revealed its IPO timeline as the firm positions itself to take advantage of India’s booming healthcare diagnostics sector. The market is forecast to expand dramatically from $16.23 billion in 2023 to $43.57 billion by fiscal year 2032, based on research from Polaris Market Research.

The company’s strategy centers on expanding its presence in sophisticated radiology and laboratory testing services, as India faces mounting healthcare challenges from demographic shifts and disease patterns. The nation’s elderly population is expected to surge, with those 60 and older projected to represent more than 20% of the total population by 2050, according to United Nations Population Fund data.

This demographic transformation, combined with increased health consciousness among citizens, is fueling greater demand for medical testing as chronic conditions like diabetes and cardiovascular disease become more prevalent.

“Our revenue from radiology is around 22% of the total and from advanced pathology is 15%, and we expect radiology to contribute to a third of the revenue and two-thirds from pathology (including advanced),” explained Chairman and Managing Director GSK Velu in an interview with Reuters.

While Velu confirmed the IPO timeline, he declined to provide specifics regarding the offering’s size or the company’s target market valuation.

The diagnostics firm operates approximately 200 clinical laboratories plus numerous sample collection facilities throughout India. Market research company Tracxn valued the business at $547 million as of December 2024.

For comparison, publicly traded competitors Metropolis Healthcare and Thyrocare Technologies currently hold market valuations of 95.06 billion rupees ($1.03 billion) and 57.13 billion rupees respectively.

Neuberg has set ambitious financial targets, aiming to achieve 20 billion rupees in revenue by fiscal 2027, representing significant growth from the 16 billion rupees the company anticipates earning in fiscal 2026. Beyond India’s borders, the firm also provides services in South Africa and operates a genetics laboratory in the United States, Velu noted.